SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 198.69+2.0%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (13514)1/20/1998 11:23:00 AM
From: Flagrante Delictu  Read Replies (4) of 32384
 
Andy, >> expectation on whether clinicals on prostate & ovarian cancer will be positive<<. At the breakout session after the LGND presentation at H&Q, Dr. Steven Reich seemed to indicate that LGND would be going forward in the areas of NSCLC, prostate, ovarian, & breast cancer. That being so, one would assume that their clinicals are at least sufficient in the eyes of the co. Maybe medsunman & Vector 1 could comment on their interpretation of what was said in this area. For their information, I was the guy who asked DR about any progress on the leptin deal, which elicited his response that if it were not done shortly with the original target, it would be brought to the fallback suitor for a presumably quick consumation {IYWPTE}. Bernie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext